|
DK1725528T3
(da)
|
2004-03-11 |
2013-09-02 |
4Sc Ag |
Sulfonylpyrroler som hdac-inhibitorer
|
|
BRPI0511504A
(pt)
|
2004-05-26 |
2008-01-22 |
Eisai R&D Man Co Ltd |
composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
|
|
US7781478B2
(en)
|
2004-07-14 |
2010-08-24 |
Ptc Therapeutics, Inc. |
Methods for treating hepatitis C
|
|
MY179032A
(en)
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
ATE458729T1
(de)
|
2004-10-26 |
2010-03-15 |
Eisai R&D Man Co Ltd |
Amorphe form einer zimtsäureamidverbindung
|
|
EP1856053A1
(en)
|
2005-01-14 |
2007-11-21 |
Millennium Pharmaceuticals, Inc. |
Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
|
|
PT1861365E
(pt)
|
2005-03-15 |
2009-09-22 |
4Sc Ag |
N-sulfonilpirroles e a sua utilização como inibidores de histona-desacetilase
|
|
CR9465A
(es)
*
|
2005-03-25 |
2008-06-19 |
Surface Logix Inc |
Compuestos mejorados farmacocineticamente
|
|
FR2886844B1
(fr)
*
|
2005-06-09 |
2007-09-14 |
Oreal |
Utilisation de composes 2-oxy-acetamide pour favoriser et/ou induire et/ou stimuler la pigmentation des matieres keratiniques et/ou limiter leur depigmentation et/ou leur blanchiment
|
|
ES2580108T3
(es)
|
2005-07-11 |
2016-08-19 |
Aerie Pharmaceuticals, Inc |
Compuestos de isoquinolina
|
|
PT1928872E
(pt)
|
2005-09-21 |
2012-05-25 |
4Sc Ag |
Utilização de novos sulfonilpirroles como inibidores de hdacs
|
|
JP5305909B2
(ja)
|
2005-09-21 |
2013-10-02 |
フォーエスシー アクチエンゲゼルシャフト |
ヒストンデアセチラーゼインヒビターとしてのスルホニルピロール塩酸塩
|
|
AU2006316005A1
(en)
*
|
2005-11-18 |
2007-05-24 |
Eisai R & D Management Co., Ltd. |
Process for production of cinnamamide derivative
|
|
JPWO2007058304A1
(ja)
*
|
2005-11-18 |
2009-05-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
シンナミド化合物の塩またはそれらの溶媒和物
|
|
MY144960A
(en)
*
|
2005-11-24 |
2011-11-30 |
Eisai R&D Man Co Ltd |
Morpholine type cinnamide compound
|
|
TWI370130B
(en)
*
|
2005-11-24 |
2012-08-11 |
Eisai R&D Man Co Ltd |
Two cyclic cinnamide compound
|
|
CN103214484B
(zh)
|
2005-12-13 |
2016-07-06 |
因塞特控股公司 |
作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
|
|
US7989461B2
(en)
|
2005-12-23 |
2011-08-02 |
Amgen Inc. |
Substituted quinazolinamine compounds for the treatment of cancer
|
|
JP5583346B2
(ja)
*
|
2006-01-18 |
2014-09-03 |
エルジー ハウスホールド アンド ヘルスケア リミテッド |
ｃ−Ｋｉｔ活性阻害剤、及び、肌美白剤
|
|
TWI378091B
(en)
|
2006-03-09 |
2012-12-01 |
Eisai R&D Man Co Ltd |
Multi-cyclic cinnamide derivatives
|
|
JP5606734B2
(ja)
|
2006-04-25 |
2014-10-15 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
|
KR20090016591A
(ko)
*
|
2006-05-19 |
2009-02-16 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
헤테로사이클 타입의 신나미드 유도체
|
|
US7737141B2
(en)
*
|
2006-07-28 |
2010-06-15 |
Eisai R&D Management Co., Ltd. |
Prodrug of cinnamide compound
|
|
ES2729424T3
(es)
|
2006-09-20 |
2019-11-04 |
Aerie Pharmaceuticals Inc |
Inhibidores de Rho cinasa
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8455513B2
(en)
|
2007-01-10 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-aminoisoquinoline compounds
|
|
US20080207900A1
(en)
*
|
2007-02-28 |
2008-08-28 |
Teiji Kimura |
Two cyclic oxomorphorin derivatives
|
|
US8263588B2
(en)
|
2007-04-06 |
2012-09-11 |
Neurocrine Biosciences, Inc. |
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
|
|
NZ580457A
(en)
|
2007-04-06 |
2012-03-30 |
Neurocrine Biosciences Inc |
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
|
|
CN101679360A
(zh)
*
|
2007-05-16 |
2010-03-24 |
卫材R&D管理有限公司 |
一步生产肉桂酰胺衍生物的方法
|
|
HUE029236T2
(en)
|
2007-06-13 |
2017-02-28 |
Incyte Holdings Corp |
(R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
|
|
KR20120107538A
(ko)
|
2007-08-22 |
2012-10-02 |
아이알엠 엘엘씨 |
키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
|
|
ES2529648T3
(es)
|
2007-08-31 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Compuesto policíclico
|
|
US7935815B2
(en)
*
|
2007-08-31 |
2011-05-03 |
Eisai R&D Management Co., Ltd. |
Imidazoyl pyridine compounds and salts thereof
|
|
BRPI0818533B8
(pt)
|
2007-10-11 |
2021-05-25 |
Astrazeneca Ab |
composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
|
|
JP5544296B2
(ja)
|
2007-11-16 |
2014-07-09 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
|
|
ES2553340T3
(es)
|
2007-12-12 |
2015-12-07 |
Rigel Pharmaceuticals, Inc. |
Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
|
|
EA201000675A1
(ru)
*
|
2007-12-18 |
2011-06-30 |
Гленмарк Фармасьютикалс, С.А. |
Производные хромана как модуляторы trpv3
|
|
US8455514B2
(en)
|
2008-01-17 |
2013-06-04 |
Aerie Pharmaceuticals, Inc. |
6-and 7-amino isoquinoline compounds and methods for making and using the same
|
|
US20100317860A1
(en)
*
|
2008-01-28 |
2010-12-16 |
Ikuo Kushida |
Crystalline cinnamide compounds or salts thereof
|
|
EP2297153B1
(en)
|
2008-04-21 |
2015-05-27 |
Lexicon Pharmaceuticals, Inc. |
Limk2 inhibitors, compositions comprising them, and methods of their use
|
|
JP5658138B2
(ja)
|
2008-04-23 |
2015-01-21 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
代謝障害の処置のためのカルボキサミド化合物
|
|
WO2010004379A2
(en)
|
2008-06-17 |
2010-01-14 |
Glenmark Pharmaceuticals S.A. |
Chromane derivatives as trpv3 modulators
|
|
US8450344B2
(en)
|
2008-07-25 |
2013-05-28 |
Aerie Pharmaceuticals, Inc. |
Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
|
|
HRP20140395T1
(hr)
*
|
2008-08-20 |
2014-06-06 |
Zoetis Llc |
SPOJEVI PIROLO[2,3-d]PIRIMIDINA
|
|
WO2010052448A2
(en)
*
|
2008-11-05 |
2010-05-14 |
Ucb Pharma S.A. |
Fused pyrazine derivatives as kinase inhibitors
|
|
EP3828172A1
(en)
|
2009-05-01 |
2021-06-02 |
Aerie Pharmaceuticals, Inc. |
Dual mechanism inhibitors for the treatment of disease
|
|
EP2432472B1
(en)
|
2009-05-22 |
2019-10-02 |
Incyte Holdings Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
MY156727A
(en)
|
2009-05-22 |
2016-03-15 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
IN2012DN02577A
(enExample)
*
|
2009-10-15 |
2015-08-28 |
Pfizer |
|
|
US20110130415A1
(en)
|
2009-12-01 |
2011-06-02 |
Rajinder Singh |
Protein kinase c inhibitors and uses thereof
|
|
US8198285B2
(en)
|
2010-01-19 |
2012-06-12 |
Astrazeneca Ab |
Pyrazine derivatives
|
|
EP3354652B1
(en)
|
2010-03-10 |
2020-05-06 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
AR084691A1
(es)
|
2010-05-21 |
2013-06-05 |
Incyte Corp |
Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
|
|
US9464078B2
(en)
|
2010-09-23 |
2016-10-11 |
Abbvie Inc. |
Monohydrate of azaadamantane derivatives
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
WO2012131399A1
(en)
|
2011-04-01 |
2012-10-04 |
Astrazeneca Ab |
Therapeutic treatment
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
PT2785349T
(pt)
|
2011-11-30 |
2019-12-11 |
Astrazeneca Ab |
Tratamento combinado de cancro
|
|
ES2593533T3
(es)
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
|
AU2013204533B2
(en)
|
2012-04-17 |
2017-02-02 |
Astrazeneca Ab |
Crystalline forms
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
US9181261B2
(en)
*
|
2012-05-22 |
2015-11-10 |
Merck Sharp & Dohme Corp. |
TrkA kinase inhibitors, compositions and methods thereof
|
|
TWI761825B
(zh)
|
2012-11-15 |
2022-04-21 |
美商英塞特控股公司 |
盧梭利替尼之緩釋性劑型
|
|
AR094929A1
(es)
|
2013-02-28 |
2015-09-09 |
Bristol Myers Squibb Co |
Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
|
|
WO2014134391A1
(en)
|
2013-02-28 |
2014-09-04 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
|
|
MX384910B
(es)
|
2013-03-06 |
2025-03-14 |
Incyte Holdings Corp |
Procesos e intermedios para hacer un inhibidor de jak.
|
|
US20140275160A1
(en)
|
2013-03-15 |
2014-09-18 |
Aerie Pharmaceuticals, Inc. |
Combination therapy
|
|
SG11201600815WA
(en)
|
2013-08-07 |
2016-03-30 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
CN103910715B
(zh)
*
|
2014-03-26 |
2016-03-02 |
深圳翰宇药业股份有限公司 |
一种别嘌醇杂质c的合成方法
|
|
US9527812B2
(en)
|
2014-05-01 |
2016-12-27 |
Northwestern University |
N-heterocyclic carbene-catalyzed synthesis of 2-aryl indoles
|
|
EP3140298A1
(en)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
AU2015317741B2
(en)
|
2014-09-17 |
2020-01-16 |
Bristol-Myers Squibb Company |
MK2 inhibitors and uses thereof
|
|
US10457669B2
(en)
|
2015-10-21 |
2019-10-29 |
Otsuka Pharmaceutical Co., Ltd. |
Benzolactam compounds as protein kinase inhibitors
|
|
US9643927B1
(en)
|
2015-11-17 |
2017-05-09 |
Aerie Pharmaceuticals, Inc. |
Process for the preparation of kinase inhibitors and intermediates thereof
|
|
JP6832946B2
(ja)
|
2015-11-17 |
2021-02-24 |
アエリエ ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤およびその中間体の調製方法
|
|
US10894784B2
(en)
|
2015-12-18 |
2021-01-19 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
EP3455216B1
(en)
*
|
2016-05-12 |
2020-11-04 |
Boehringer Ingelheim International GmbH |
Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
CN107663202B
(zh)
*
|
2016-07-29 |
2020-09-04 |
西华大学 |
3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
|
|
CN109640966A
(zh)
|
2016-08-31 |
2019-04-16 |
爱瑞制药公司 |
眼用组合物
|
|
EP3872080B1
(en)
|
2016-09-02 |
2023-08-16 |
Cyclerion Therapeutics, Inc. |
Fused bicyclic sgc stimulators
|
|
WO2018165520A1
(en)
|
2017-03-10 |
2018-09-13 |
Vps-3, Inc. |
Metalloenzyme inhibitor compounds
|
|
WO2018183911A1
(en)
|
2017-03-31 |
2018-10-04 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
US11186554B2
(en)
*
|
2017-05-03 |
2021-11-30 |
Vivace Therapeutics, Inc. |
Non-fused tricyclic compounds
|
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
JP7393348B2
(ja)
|
2018-01-30 |
2023-12-06 |
インサイト・コーポレイション |
（１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
|
|
BR122023024273A2
(pt)
|
2018-02-27 |
2024-02-20 |
Incyte Corporation |
Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
|
|
CN113768934A
(zh)
|
2018-03-30 |
2021-12-10 |
因赛特公司 |
使用jak抑制剂治疗化脓性汗腺炎
|
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
US11427563B2
(en)
|
2018-09-14 |
2022-08-30 |
Aerie Pharmaceuticals, Inc. |
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020089025A1
(en)
|
2018-10-29 |
2020-05-07 |
Boehringer Ingelheim International Gmbh |
Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
|
|
SG11202102440SA
(en)
|
2018-10-29 |
2021-04-29 |
Boehringer Ingelheim Int |
Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
WO2021021979A2
(en)
|
2019-07-30 |
2021-02-04 |
Eikonizo Therapapeutics, Inc. |
Hdac6 inhibitors and uses thereof
|
|
CN116348458A
(zh)
|
2019-08-14 |
2023-06-27 |
因赛特公司 |
作为cdk2抑制剂的咪唑基嘧啶基胺化合物
|
|
CN114585606A
(zh)
*
|
2019-08-29 |
2022-06-03 |
希伯塞尔股份有限公司 |
抑制perk的化合物
|
|
CN119930611A
(zh)
|
2019-10-11 |
2025-05-06 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
|
EP4445902A3
(en)
|
2019-12-24 |
2024-12-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN117964757A
(zh)
|
2020-02-14 |
2024-05-03 |
吉利德科学公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
AU2022376954B2
(en)
|
2021-10-29 |
2026-04-23 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
AU2022419982B2
(en)
|
2021-12-22 |
2026-04-16 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
EP4493554A1
(en)
|
2022-03-17 |
2025-01-22 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4504190A4
(en)
|
2022-04-08 |
2026-03-25 |
Eikonizo Therapeutics Inc |
OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
PE20250758A1
(es)
|
2022-07-01 |
2025-03-13 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
CN120225509A
(zh)
|
2022-12-22 |
2025-06-27 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026015873A1
(en)
*
|
2024-07-12 |
2026-01-15 |
Kymera Therapeutics, Inc. |
Stat6 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2026089992A1
(en)
|
2024-10-21 |
2026-04-30 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|